PCM
RVNC

Pyrrho Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Pyrrho Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-25,000
Closed -$854K – 25
2015
Q4 		$854K Buy
+25,000
New +$867K 0.58% 11

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pyrrho Capital Management's RVNC Position: Q1 2016 in Review

Pyrrho Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2016, closing a stake of 25,000 shares — an estimated $854K sold.

Pyrrho Capital Management first reported a position in RVNC in Q4 2015 and held it in 1 quarter. The position peaked at $854K in Q4 2015. 86 funds tracked by Wall St. Rank hold RVNC as of Q1 2016.

  • Pyrrho Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Pyrrho Capital Management sold 25,000 Revance Therapeutics, Inc. shares in Q1 2016, an estimated $854K.
  • Pyrrho Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Pyrrho Capital Management's Revance Therapeutics, Inc. position peaked at $854K in Q4 2015.
  • 86 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2016.

Based on Pyrrho Capital Management's 13F filing for Q1 2016, filed 13 May 2016.